Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of daunorubicin and cytarabine liposome for injection in adults with newly diagnosed high-risk secondary acute myeloid leukemia
CTR20233839Phase 2Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by CSPC Zhongnuo Pharmaceutical. Started Mar 2024; status: active.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20233839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233839.